Clinical outcome study of crizotinib in IHC proven EML4-ALK fusion gene among Indian patients with adenocarcinoma lung

被引：0
|
作者：
Batra, U. [1 ]
Sharma, M. [2 ]
Jain, A. [1 ]
Agarwal, M. [1 ]
Goyal, P. [2 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst, Med Oncol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
469P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preliminary Orthogonal Analysis of EML4-ALK Gene Fusion Detection Methods in Chilean Patients with Lung Adenocarcinoma
    Freire, M.
    Lizana, R.
    Ramos, L.
    Sepulveda-Hermosilla, G.
    Blanco, A.
    Perez, P.
    Aren, O.
    Chernilo, S.
    Fernandez, C.
    Armisen, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S163 - S164
  • [22] Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma
    Jiang, Liqun
    Chen, Suping
    Stinnett, Victoria
    Haley, Lisa
    Morsberger, Laura
    Shane, Alison
    Hardy, Melanie
    Smith, Kirstin
    Gocke, Christopher D.
    Lin, Ming-Tseh
    Zhou, Ying S.
    CANCER GENETICS, 2021, 258 : 18 - 22
  • [23] Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
    Maillet, Denis
    Martel-Lafay, Isabelle
    Arpin, Dominique
    Perol, Maurice
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : E30 - E31
  • [24] Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Transtocation with Adnexal Metastasis
    Wang, Wenxian
    Jin, Ying
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1176 - S1176
  • [25] Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer
    Dai, Ying
    Wei, Quanxiang
    Schwager, Christian
    Moustafa, Mahmoud
    Zhou, Cheng
    Lipson, Kenneth E.
    Weichert, Wilko
    Debus, Juergen
    Abdollahi, Amir
    RADIOTHERAPY AND ONCOLOGY, 2015, 114 (02) : 173 - 181
  • [26] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    Koivunen, Jussi P.
    Mermel, Craig
    Zejnullahu, Kreshnik
    Murphy, Carly
    Lifshits, Eugene
    Holmes, Alison J.
    Choi, Hwan Geun
    Kim, Jhingook
    Chiang, Derek
    Thomas, Roman
    Lee, Jinseon
    Richards, William G.
    Sugarbaker, David J.
    Ducko, Christopher
    Lindeman, Neal
    Marcoux, J. Paul
    Engelman, Jeffrey A.
    Gray, Nathanael S.
    Lee, Charles
    Meyerson, Matthew
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4275 - 4283
  • [27] A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene
    Chen, Xiaoxia
    Zhang, Jie
    Hu, Qiong
    Li, Xuefei
    Zhou, Caicun
    LUNG CANCER, 2013, 81 (02) : 308 - 310
  • [28] Clinicopathological features of younger (aged 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene
    Kometani, Takuro
    Sugio, Kenji
    Osoegawa, Atsushi
    Seto, Takashi
    Ichinose, Yukito
    THORACIC CANCER, 2018, 9 (05) : 563 - 570
  • [29] Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients (NSCLC)
    Aguado, Cristina
    Teixido, Cristina
    Gimenez-Capitan, Ana
    Gil, Maria de los Llanos
    Rodriguez, Sonia
    Viteri, Santiago
    Karachaliou, Niki
    Aldeguer, Erika
    Peg, Vicente
    Alonso, Lidia
    Molina-Vila, Miguel Angel
    Rosell, Rafael
    CANCER RESEARCH, 2017, 77
  • [30] The frequency of EML4-ALK gene rearrangement in primary lung adenocarcinoma cases of Turkish patients
    Kaya, H.
    Bozkurtlar, E.
    Kombak, E.
    Toper, H.
    VIRCHOWS ARCHIV, 2014, 465 : S322 - S322
12345